| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
143,520,000 |
| Market
Cap: |
63.51(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.4425 - $0.4425 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile EyePoint Pharmaceuticals is a pharmaceutical company focused on developing and commercializing therapeutics for patients with eye disorders. Co.'s primary product candidate, EYP-19, is a potential sustained delivery intravitreal anti-VEGF treatment targeting wet age-related macular degeneration. YUTIQ 50 (fluocinolone acetonide intravitreal implant) 0.18 mg for intravitreal injection, is for the treatment of non-infectious uveitis affecting the posterior segment of the eye. DEXYCU® (dexamethasone intraocular suspension) 9%, for intraocular administration, is indicated for the treatment of post-operative ocular inflammation.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
1,431,765 |
4,794,057 |
4,794,057 |
4,794,057 |
| Total Buy Value |
$20,571,167 |
$89,496,413 |
$89,496,413 |
$89,496,413 |
| Total People Bought |
1 |
1 |
1 |
1 |
| Total Buy Transactions |
2 |
6 |
6 |
6 |
| Total Shares Sold |
0 |
6,161,499 |
6,722,029 |
6,722,029 |
| Total Sell Value |
$0 |
$121,266,413 |
$128,353,600 |
$128,353,600 |
| Total People Sold |
0 |
6 |
7 |
7 |
| Total Sell Transactions |
0 |
24 |
32 |
32 |
| End Date |
2024-02-15 |
2023-11-14 |
2023-05-16 |
2022-05-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Paggiarino Dario A. |
Chief Medical Officer |
• – – |
2020-06-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
14,200 |
57,247 |
|
- |
|
| Elston George |
Chief Financial Officer |
• – – |
2020-03-12 |
4 |
B |
$0.96 |
$9,600 |
D/D |
10,000 |
20,000 |
0.01 |
-21% |
|
| Lurker Nancy |
President & CEO |
• • – |
2020-03-10 |
4 |
B |
$1.06 |
$104,027 |
D/D |
98,000 |
574,800 |
0.01 |
-30% |
|
| Lurker Nancy |
President & CEO |
• • – |
2020-02-21 |
4 |
OE |
$0.00 |
$0 |
D/D |
137,174 |
476,800 |
|
- |
|
| Elston George |
Chief Financial Officer |
• – – |
2019-11-15 |
4 |
B |
$1.43 |
$14,290 |
D/D |
10,000 |
10,000 |
0.01 |
- |
|
| Lurker Nancy |
President & CEO |
• • – |
2019-10-12 |
4 |
D |
$2.11 |
$22,618 |
D/D |
(10,745) |
314,455 |
|
- |
|
| Paggiarino Dario A. |
Chief Medical Officer |
• – – |
2019-10-12 |
4 |
D |
$2.11 |
$5,157 |
D/D |
(2,450) |
43,047 |
|
- |
|
| Mazzo David J |
|
– • – |
2019-10-09 |
4 |
OE |
$1.95 |
$64,999 |
D/D |
33,333 |
200,083 |
|
- |
|
| Mazzo David J |
|
– • – |
2019-09-06 |
4 |
OE |
$0.00 |
$0 |
D/D |
417 |
166,750 |
|
- |
|
| Lurker Nancy |
President & CEO |
• • – |
2019-06-27 |
4 |
OE |
$0.00 |
$0 |
D/D |
40,000 |
325,200 |
|
- |
|
| Paggiarino Dario A. |
Chief Medical Officer |
• – – |
2019-06-27 |
4 |
D |
$1.65 |
$4,851 |
D/D |
(2,940) |
45,497 |
|
- |
|
| Paggiarino Dario A. |
Chief Medical Officer |
• – – |
2019-06-27 |
4 |
OE |
$0.00 |
$0 |
D/D |
10,000 |
48,437 |
|
- |
|
| Ross Leonard S |
See Remarks |
• – – |
2019-06-27 |
4 |
D |
$1.65 |
$3,236 |
D/D |
(1,961) |
90,044 |
|
- |
|
| Ross Leonard S |
See Remarks |
• – – |
2019-06-27 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,667 |
92,005 |
|
- |
|
| Godshall Douglas Evan |
|
– • – |
2019-06-21 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,667 |
36,167 |
|
- |
|
| Duker Jay S. |
|
– • – |
2019-06-21 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,667 |
44,167 |
|
- |
|
| Mazzo David J |
|
– • – |
2019-06-21 |
4 |
OE |
$0.00 |
$0 |
D/D |
8,333 |
166,333 |
|
- |
|
| Peterson Kristine |
|
– • – |
2019-06-21 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,667 |
6,667 |
|
- |
|
| Rogers Michael W |
|
– • – |
2019-06-21 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,667 |
119,167 |
|
- |
|
| Lurker Nancy |
President & CEO |
• • – |
2019-06-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
45,000 |
285,200 |
|
- |
|
| Paggiarino Dario A. |
Chief Medical Officer |
• – – |
2019-06-14 |
4 |
D |
$1.53 |
$6,388 |
D/D |
(4,175) |
38,437 |
|
- |
|
| Paggiarino Dario A. |
Chief Medical Officer |
• – – |
2019-06-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
14,200 |
42,612 |
|
- |
|
| Ross Leonard S |
See Remarks |
• – – |
2019-06-14 |
4 |
D |
$1.53 |
$3,663 |
D/D |
(2,394) |
85,338 |
|
- |
|
| Ross Leonard S |
See Remarks |
• – – |
2019-06-14 |
4 |
OE |
$0.00 |
$0 |
D/D |
8,280 |
87,732 |
|
- |
|
| Duker Jay S. |
|
– • – |
2019-04-12 |
4 |
OE |
$1.77 |
$35,400 |
D/D |
20,000 |
37,500 |
|
- |
|
252 Records found
|
|
Page 7 of 11 |
|
|
